Analysis of force developed by a AAA ATPase
AAA ATP酶产生的力分析
基本信息
- 批准号:8334589
- 负责人:
- 金额:$ 30.81万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-09-30 至 2015-08-31
- 项目状态:已结题
- 来源:
- 关键词:ATP HydrolysisATP phosphohydrolaseAddressAffectAmino AcidsApoptosisBacteriaBindingBiogenesisBiological ClocksBiologyCell CycleCell divisionCell physiologyClinical TreatmentClinical TrialsCommitDecision TreesDevicesDigestionFailureFamilyGene Expression RegulationGenerationsGenetic TranscriptionGoalsHalf-LifeHandHealthHumanIndividualLengthMalignant NeoplasmsMeasurementMeasuresMethodsMitochondriaModelingMolecular MachinesMovementMultiple MyelomaMultivesicular BodyMutateNervous System TraumaOutcomePathologyPerformancePropertyProteasome InhibitorProteinsProteolysisRecurrenceRegulationRoleSideSignal Transduction PathwaySiteStatistical DistributionsStressSurfaceSystemTechniquesTestingTherapeutic InterventionTimeTransport Protein GeneWarWorkantigen processingdesensitizationhuman diseaseinsightmembermulticatalytic endopeptidase complexpolypeptideprotein degradationreceptorsingle molecule
项目摘要
DESCRIPTION (provided by applicant): The AAA ATPases family includes molecules whose roles include, but are far from limited to, biogenesis of mitochondria and multivesicular bodies, proteins in involved in gene regulation and protein transport. This project will focus on studying the activity of these machines at the single molecule level. The model protein will be ClpX - it is the part of the proteosome, a key effect of protein degradation that unfolds the proteins to prepare them for degradation. . Cellular proteins differ widely in their liability, from half-lives of minutes to days. Regulated degradation, by allowing rapid changes in the levels of cellular proteins, helps control signal transduction pathways, the cell- cycle, transcription, apoptosis, antigen processing, biological clock control, differentiation and surface receptor desensitization. The questions to be addressed are: How is work partitioned between alternative outcomes? What is the maximum work that can be performed by the system? What factors limit its efficiency in performing work? These questions have health implications: human pathological conditions are associated with failures of the degradation system and its regulation offers the potential for therapeutic intervention. Furthermore, an inhibitor of proteasome catalytic activity is in use for treatment of recurrent multiple myeloma, and proteasome inhibitors are in clinical trial for treatment of a broad spectrum of human malignancies. Thus, understanding the regulation of the half-life of proteins should provide critical insights into cell physiology and pathology. The mishandling of aberrant proteins incurs penalties throughout biology: the survival of bacteria subjected to stress depends on the effective performance of systems which deal with misfolded and structurally aberrant proteins- to either fold them properly or destroy them. The specific questions to be addressed are: How hard can the device pull to cause unfolding? How many pulls are needed to commit irreversibly? What is the limit of pulling power, and the statistical distribution of pulling power? Answers to these questions will begin to reveal not just what these machines do but the decision tree that describes how outcomes are controlled and when machine capacity may be exceeded. We want to know not just how the machine works, but how its decision tree yields alternative outcomes.
描述(由申请人提供):AAA ATPASE家族包括其作用的分子,其作用包括但远非仅限于线粒体的生物发生和多重囊体的生物发生,参与基因调节和蛋白质转运的蛋白质。该项目将着重研究这些机器在单分子水平上的活性。模型蛋白将是CLPX - 它是蛋白质体的一部分,蛋白质降解的关键作用将展现蛋白质以使其为降解做好准备。 。细胞蛋白的责任差异很大,从半数分钟到几天。通过允许细胞蛋白水平的快速变化,受调节的降解有助于控制信号转导途径,细胞周期,转录,凋亡,抗原加工,抗原加工,生物钟控制,分化和表面受体脱敏。要解决的问题是:如何在替代结果之间分区工作?系统可以执行的最大工作是什么?哪些因素限制了其执行工作效率?这些问题具有健康的影响:人类病理状况与降解系统的失败有关,其调节为治疗干预提供了潜力。此外,蛋白酶体催化活性的抑制剂正在用于治疗复发性多发性骨髓瘤,蛋白酶体抑制剂正在临床试验中,以治疗各种人类恶性肿瘤。因此,了解蛋白质半衰期的调节应提供对细胞生理和病理学的关键见解。异常蛋白质的不当行为会在整个生物学中受到惩罚:受到压力的细菌的存活取决于系统的有效性能,这些系统涉及处理错误的蛋白质和结构异常异常的蛋白质 - 可以正确折叠或破坏它们。要解决的具体问题是:设备可以多么难以引起展开?不可逆转地施加需要多少个拉力?拉力的限制和拉力的统计分布是什么?这些问题的答案将不仅揭示这些机器的作用,而且还会揭示描述结果如何控制以及何时超过机器容量的决策树。我们不仅要知道机器的工作原理,而且要知道其决策树如何产生替代结果。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
SANFORD M SIMON其他文献
SANFORD M SIMON的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('SANFORD M SIMON', 18)}}的其他基金
Center for therapeutic targeting of the Fusion Oncoprotein of Fibrolamellar Hepatocellular Carcinoma
纤维板层肝细胞癌融合癌蛋白治疗靶向中心
- 批准号:
10826323 - 财政年份:2023
- 资助金额:
$ 30.81万 - 项目类别:
ASO and shRNA for targeting the oncogenic transcript driving fibrolamellar hepatocellular carcinoma
ASO 和 shRNA 用于靶向驱动纤维层状肝细胞癌的致癌转录物
- 批准号:
10652432 - 财政年份:2020
- 资助金额:
$ 30.81万 - 项目类别:
ASO and shRNA for targeting the oncogenic transcript driving fibrolamellar hepatocellular carcinoma
ASO 和 shRNA 用于靶向驱动纤维层状肝细胞癌的致癌转录物
- 批准号:
10171814 - 财政年份:2020
- 资助金额:
$ 30.81万 - 项目类别:
ASO and shRNA for targeting the oncogenic transcript driving fibrolamellar hepatocellular carcinoma
ASO 和 shRNA 用于靶向驱动纤维层状肝细胞癌的致癌转录物
- 批准号:
10412971 - 财政年份:2020
- 资助金额:
$ 30.81万 - 项目类别:
Center for therapeutic targeting of the Fusion Oncoprotein of Fibrolamellar Hepatocellular Carcinoma
纤维板层肝细胞癌融合癌蛋白治疗靶向中心
- 批准号:
10221308 - 财政年份:2019
- 资助金额:
$ 30.81万 - 项目类别:
Cellular Pathogenesis of Fibrolamellar Hepatocellular Carcinoma
纤维板层肝细胞癌的细胞发病机制
- 批准号:
9158744 - 财政年份:2016
- 资助金额:
$ 30.81万 - 项目类别:
相似海外基金
Inhibition or evasion of P-glycoprotein-mediated drug transport
抑制或逃避 P-糖蛋白介导的药物转运
- 批准号:
10568723 - 财政年份:2023
- 资助金额:
$ 30.81万 - 项目类别:
Targeting Energetics to Improve Outcomes in Hypertrophic Cardiomyopathy
靶向能量药物以改善肥厚型心肌病的预后
- 批准号:
10687401 - 财政年份:2022
- 资助金额:
$ 30.81万 - 项目类别:
Structure and function of mitochondrial Hsp60
线粒体 Hsp60 的结构和功能
- 批准号:
10406155 - 财政年份:2021
- 资助金额:
$ 30.81万 - 项目类别:
Integrating Stochasticity into Biomolecular Mechanisms: A New Direction for Biomolecular Modeling
将随机性整合到生物分子机制中:生物分子建模的新方向
- 批准号:
10277296 - 财政年份:2021
- 资助金额:
$ 30.81万 - 项目类别: